Compass Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage, oncology-focused biopharmaceutical company that develops proprietary antibody-based therapeutics targeting multiple biological pathways essential for anti-tumor immune responses, including angiogenesis inhibition, immune co-stimulation, and checkpoint inhibition; its lead product candidate, tovecimig (CTX-009), is a bispecific antibody targeting Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) in Phase 2/3 trials for biliary tract cancer and Phase 1b studies for solid tumors such as colorectal, gastric, ovarian, renal, and hepatocellular carcinoma; CTX-471 is an agonistic IgG4 monoclonal antibody targeting CD137 (4-1BB) for co-stimulation of T cells and innate immune cells in Phase 1 trials for solid tumors and hematologic malignancies; CTX-8371 is a bispecific antibody targeting PD-1 and PD-L1 in IND-enabling preclinical development; and CTX-10726 is a bispecific antibody targeting PD-1 and VEGF-A advancing toward IND filing by year-end 2025, with additional preclinical bispecifics evaluating VEGF combinations with immune targets. Founded in 2014 and headquartered in Boston, Massachusetts, the company operates primarily in the United States through its proprietary StitchMabs and common light chain antibody discovery platforms, leveraging partnerships such as its 2018 exclusive global license (ex-South Korea) with ABL Bio for tovecimig and a 2014 collaboration with Adimab for antibody discovery including CTX-471. Recent developments include pricing an upsized $120 million public offering of common stock in August 2025 to fund clinical advancement, commercial readiness preparations, and research; anticipation of progression-free survival and overall survival data from the COMPANION-002 Phase 2/3 trial of tovecimig plus paclitaxel in advanced biliary tract cancer by late Q1 2026 following achievement of the 17.1% overall response rate primary endpoint; planned initiation of CTX-471 expansion cohorts in Q4 2025 with Phase 1 data in H1 2026; and upcoming U.S. clinical studies for CTX-009 in multiple solid tumor indications in H1 2026.
Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
Compass Therapeutics to Participate in Upcoming June Investor Events
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Compass Therapeutics to Participate in Upcoming May Investor Events
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 Study in Advanced Biliary Tract Cancer Transcript
Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer